M. Negri's Profile

Role	Title	Level	Year	L/R
🐜	17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: Protein structures, functions, and recent progress in inhibitor development 13 auth. S. Marchais-Oberwinkler, C. Henn, G. Möller, T. Klein, M. Negri, Alexander Oster, A. Spadaro, R. Werth, M. Wetzel, Kuiying Xu, ... Martin Frotscher, R. Hartmann, J. Adamski	7	2011	7 🐜
🐜	Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). 10 auth. Emmanuel Bey, S. Marchais-Oberwinkler, R. Werth, M. Negri, Yaseen A. Al-Soud, Patricia Kruchten, ... Alexander Oster, Martin Frotscher, B. Birk, R. Hartmann	6	2008	6 🐜
🐜	Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure. 14 auth. Carsten Jagusch, M. Negri, Ulrike E. Hille, Qingzhong Hu, M. Bartels, Kerstin Jahn-Hoffmann, Mariano A E Pinto-Bazurco Mendieta, Barbara Rodenwaldt, U. Müller‐Vieira, D. Schmidt, ... Thomas Lauterbach, M. Recanatini, A. Cavalli, R. Hartmann	6	2008	6 🐜
🐜	New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity. 11 auth. Emmanuel Bey, S. Marchais-Oberwinkler, M. Negri, Patricia Kruchten, Alexander Oster, T. Klein, ... A. Spadaro, R. Werth, Martin Frotscher, B. Birk, R. Hartmann	6	2009	6 🐜
🐜	Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. 9 auth. S. Lucas, Ralf Heim, M. Negri, I. Antes, C. Ries, K. Schewe, ... A. Bisi, S. Gobbi, R. Hartmann	6	2008	6 🐜
🐜	Imidazolylmethylbenzophenones as highly potent aromatase inhibitors. 9 auth. S. Gobbi, A. Cavalli, M. Negri, K. Schewe, F. Belluti, Lorna Piazzi, ... R. Hartmann, M. Recanatini, A. Bisi	6	2007	6 🐜
🐜	Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls. 8 auth. Ulrike E. Hille, Qingzhong Hu, Carsten A. Vock, M. Negri, M. Bartels, U. Müller‐Vieira, ... Thomas Lauterbach, R. Hartmann	6	2009	6 🐜
🐬	Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer. Mariano A E Pinto-Bazurco Mendieta, M. Negri, Carsten Jagusch, U. Müller‐Vieira, Thomas Lauterbach, R. Hartmann	5	2008	5 🐬
🐬	Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives. S. Lucas, M. Negri, Ralf Heim, Christina Zimmer, R. Hartmann	5	2011	5 🐬